Prime Medicine, Inc.
Prime Medicine is a biotechnology company developing genetic medicines for diseases caused by defined genetic alterations, cellular dysfunction or dysregulated gene expression. Its platform uses Prime Editing to make targeted changes to genomic DNA. The pipeline includes in vivo programs for Wilson Disease and alpha-1 antitrypsin deficiency, an early-stage Cystic Fibrosis program, and PM359, an ex vivo program for chronic granulomatous disease. Prime Medicine also collaborates with Bristol-Myers Squibb on ex vivo T-cell engineering for oncology and immunology indications. Prime Medicine develops candidates for its own pipeline and licenses Prime Editing technology to partners. Under its collaboration with Bristol-Myers Squibb, it designs editing reagents, while Bristol-Myers Squibb holds an exclusive worldwide license for certain ex vivo T-cell products and Prime Medicine is eligible for milestone payments and royalties on sales. The company is headquartered in Cambridge, Massachusetts.
No SEC Form 4 filings for $PRME in the last 30 days.
See all $PRME insider activity →Jones Trading initiated coverage on Prime Medicine Inc. (NASDAQ:PRME) with a Buy rating and $6.00 price target, citing potential upside of 21%. The stock has risen 46.6% in six months. Other analysts also gave positive ratings and higher price targets, citing the company's gene editing pipeline and recent developments.
Shares of gene editing therapy companies surged this week due to positive data from the ESGCT Congress and FDA draft guidance for personalized gene therapies. Prime Medicine (PRME) rose 29%, Beam Therapeutics (BEAM) 13%, Editas Medicine (EDIT) 11%, and Intellia Therapeutics (NTLA) 11%. The FDA's guidance aims to streamline approvals for individualized genome editing products. Analysts view the developments positively, anticipating continued momentum.
Shares of gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics, Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rose after the FDA issued draft guidance to expedite personalized treatments for rare genetic diseases. The new approach allows one application for multiple versions of the same gene-editing treatment. PRME gained 20%, with other companies seeing 4-14% increases.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning PRME (Prime Medicine, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent PRME coverage spans regulation, technology and financial news.
Analyst initiation and buy rating suggest upward pressure on PRME.
Strong upside as the guidance de‑risks PRME's personalized therapy pipeline.
Positive regulatory signal likely fuels further buying.
The trial start and FDA designation are fresh, material milestones for a biotech, likely prompting buying interest.
The piece frames PRME’s technical breakout risk as structurally capped by newly issued equity supply, even as clinical dosing news drives short-term momentum.
AlphAI scores every news story that mentions PRME with an AI model for sentiment and relevance, and aggregates insider trades from Prime Medicine, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Jones Trading initiated coverage on Prime Medicine Inc. (NASDAQ:PRME) with a Buy rating and $6.00 price target, citing potential upside of 21%. The stock has risen 46.6% in six months. Other analysts also gave positive ratings and higher price targets, citing the company's gene editing pipeline and recent developments.
Shares of gene editing therapy companies surged this week due to positive data from the ESGCT Congress and FDA draft guidance for personalized gene therapies. Prime Medicine (PRME) rose 29%, Beam Therapeutics (BEAM) 13%, Editas Medicine (EDIT) 11%, and Intellia Therapeutics (NTLA) 11%. The FDA's guidance aims to streamline approvals for individualized genome editing products. Analysts view the developments positively, anticipating continued momentum.
Shares of gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics, Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rose after the FDA issued draft guidance to expedite personalized treatments for rare genetic diseases. The new approach allows one application for multiple versions of the same gene-editing treatment. PRME gained 20%, with other companies seeing 4-14% increases.
Prime Medicine's shares rose 21% to $5.27 after the company announced the first patient was dosed in a Phase 1/2 trial for PM577a, an in vivo prime editor for Wilson disease. The FDA granted rare pediatric disease designation to PM577. The trial will evaluate safety, tolerability, and preliminary efficacy in adults and adolescents with a specific genetic mutation.
Prime Medicine (PRME) is analyzed for its thin float and heavy short interest, with a focus on institutional market maker activity. The stock experienced a post-IPO markdown, a capitulation floor at $1.11, and a July 2025 volume anomaly due to a $125.4M public offering. The company's financing structure and market maker interventions are examined for their impact on the stock's price.
Citizens maintained a Market Outperform rating and $7.00 price target for Prime Medicine (NASDAQ:PRME) after its first patient dosing in a Wilson disease trial. The company's market cap is $571M, with a current ratio of 3.05. Analysts highlight Prime Medicine's clinical-stage transition and gene-editing advancements, including FDA clearance for PM647 and a favorable arbitration outcome with Beam Therapeutics.
Prime Medicine Inc. (NASDAQ:PRME) dosed the first patient in a Phase 1/2 trial for PM577a, a gene therapy for Wilson disease. The trial targets the H1069Q mutation, the most common in North America and Europe. The FDA granted Rare Pediatric Disease designation to PM577, which may qualify for a Priority Review Voucher. Initial data is expected in 2027.
Prime Medicine Inc (PRME) shares rose 12% after the FDA cleared its Investigational New Drug application for PM647, a gene therapy for Alpha-1 Antitrypsin Deficiency. The company plans a global Phase 1/2 clinical trial. This is Prime Medicine's second regulatory milestone in recent months.
Gene-editing stocks fell Wednesday after Anthropic's AI model, Claude, identified a phage enzyme system with traits similar to CRISPR. CRISPR Therapeutics (CRSP) dropped 6%, Intellia (NTLA) 3%, Beam (BEAM) 6%, Prime Medicine (PRME) 12%, and Editas Medicine (EDIT) 8%. The discovery, called ART, links an RNA-to-DNA enzyme with repeating DNA and a mystery protein in bacteria-infecting viruses. CRISPR pioneer Feng Zhang called the finding intriguing but unproven.
Prime Medicine (PRME) reported a Q2 2026 net loss of $42.1M, narrower than the prior year. R&D and G&A expenses decreased. The company advanced PM577a and PM647 toward clinical trials, with FDA clearances and data expected in 2027. PM359 received RMAT designation, with a potential BLA filing in 2027. PRME has $108.8M in cash, expected to last into 2027.
